{
    "clinical_study": {
        "@rank": "63568", 
        "acronym": "EMBRACE", 
        "arm_group": [
            {
                "arm_group_label": "Placebo + Background Therapy", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Background therapy including DMARD(s) approved by protocol"
            }, 
            {
                "arm_group_label": "BIIB057 Dose 1 + Background Therapy", 
                "arm_group_type": "Experimental", 
                "description": "Background therapy including DMARD(s) approved by protocol"
            }, 
            {
                "arm_group_label": "BIIB057 Dose 2 + Background Therapy", 
                "arm_group_type": "Experimental", 
                "description": "Background therapy including DMARD(s) approved by protocol"
            }, 
            {
                "arm_group_label": "BIIB057 Dose 3 + Background Therapy", 
                "arm_group_type": "Experimental", 
                "description": "Background therapy including DMARD(s) approved by protocol"
            }
        ], 
        "brief_summary": {
            "textblock": "Phase II study designed to evaluate the safety and efficacy of BIIB057 in Subjects with\n      Rheumatoid Arthritis who have experienced an Inadequate Response to Disease-Modifying\n      Antirheumatic Drugs (DMARDs)."
        }, 
        "brief_title": "BIIB057 in Subjects With Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult onset RA satisfying 2010 Revised ACR Criteria for the Classification of RA with\n             a disease history of at least 6 months\n\n          -  Active RA as defined by: at least 4 swollen joints (based on 28-joint count), at\n             least 4 tender joints (based on 28-joint count), and high-sensitivity CRP (hsCRP)\n             10mg/L or greater\n\n          -  No prior treatment with biologics\n\n          -  Receiving a DMARD therapy for at least 3 months, using a regimen that has been stable\n             for at least 28 days prior to screening\n\n        Exclusion Criteria:\n\n          -  History of inflammatory joint disease other than RA\n\n          -  Abnormal chest X-ray consistent with tuberculosis, malignancy, or infection\n\n          -  History of malignancy, carcinoma in situ, or high-grade dysplasia\n\n          -  History of opportunistic infection, infection requiring treatment, serious local\n             infection, recent fever, active herpes zoster or Epstein-Barr virus, or diagnosis or\n             family history of Creutzfeldt-Jakob disease.\n\n          -  Clinically significant cardiac disease\n\n          -  Treatment with prednisone >10 mg orally daily\n\n          -  Intra-articular steroid injection within 28 days before screening\n\n          -  Clinically significant abnormality in hematology or blood chemistry values at\n             screening"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01652937", 
            "org_study_id": "227RA201"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "BIIB057 Dose 3 + Background Therapy", 
                    "BIIB057 Dose 1 + Background Therapy", 
                    "BIIB057 Dose 2 + Background Therapy"
                ], 
                "description": "Oral", 
                "intervention_name": "BIIB057", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo + Background Therapy", 
                "description": "Oral", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Antirheumatic Agents"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Rheumatoid Arthritis", 
            "DMARD-IR"
        ], 
        "lastchanged_date": "September 12, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Winnipeg", 
                        "country": "Canada", 
                        "state": "Manitoba", 
                        "zip": "R3C 3J5"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Quispamsis", 
                        "country": "Canada", 
                        "state": "New Brunswick", 
                        "zip": "E2E 4J8"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M9W 4L6"
                    }, 
                    "name": "Research Site"
                }
            }
        ], 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of BIIB057 in Subjects With Rheumatoid Arthritis Who Have Had an Inadequate Response to Disease-Modifying Antirheumatic Drugs", 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": [
                "South Africa: Department of Health", 
                "Canada: Health Canada"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Proportion of subjects achieving an ACR20 response (ACR20 = American College of Rheumatology 20% response criteria change from baseline)", 
            "safety_issue": "No", 
            "time_frame": "Week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01652937"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Assess the safety and tolerability of BIIB057 by measuring the incidence of AEs, SAEs and changes in laboratory test results during the study", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 16 weeks"
            }, 
            {
                "measure": "Proportion of subjects with 28-joint count Disease Activity Score with C-reactive protein (DAS28-CRP) <3.2, <2.6, and <2.32", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }, 
            {
                "measure": "Proportion of subjects achieving ACR50 and ACR70 response", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }
        ], 
        "source": "Biogen Idec", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Biogen Idec", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}